NDLI: Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.

Please wait, while we are loading the content...

Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.

Content Provider	Semantic Scholar
Author	Selleng, Sixten Haneya, Assad Hirt, Stephan W. Selleng, Kathleen Schmid, Christof Greinacher, Andreas
Copyright Year	2008
Abstract	Anticoagulation management of patients with recent heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB) surgery is a serious challenge, and especially difficult in patients requiring urgent heart transplantation. As nonheparin anticoagulants during CPB bear a high risk of major bleeding, these patients are at risk of being taken off the transplant list. Short-term use of unfractionated heparin (UFH) for CPB, with restriction of UFH to the surgery itself, is safe and effective in patients with a history of HIT who test negative for antiplatelet factor 4 (PF4)/heparin antibodies. We present evidence that it is safe to expand the concept of UFH reexposure to patients with subacute HIT (ie, those patients with recent HIT in whom the platelet count has recovered but in whom anti-PF4/heparin IgG antibodies remain detectable) requiring heart transplantation, if they test negative by a sensitive functional assay using washed platelets. This can be lifesaving in patients with end-stage heart failure.
Starting Page	1069
Ending Page	1082
Page Count	14
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://www.bloodjournal.org/content/bloodjournal/early/2008/09/12/blood-2008-03-145243.full.pdf?sso-checked=true
PubMed reference number	18791163v1
Alternate Webpage(s)	https://doi.org/10.1182/blood-2008-03-145243
DOI	10.1182/blood-2008-03-145243
Journal	Blood
Volume Number	112
Issue Number	10
Language	English
Access Restriction	Open
Subject Keyword	Anticoagulants Blood Platelet Disorders Blood Platelets Cardiopulmonary Bypass Cooley's anemia Heart Transplantation Heart failure Hemorrhage Heparin-induced thrombocytopenia Patients Platelet Count measurement Schedule (document type) Transplanted tissue heparin
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia

Thrombosis due to Heparin-induced Thrombocytopenia in Cardiac Surgery : is Fondaparinux an Effective Treatment ?

Heparin-induced thrombocytopenia occurring after discontinuation of heparin.

Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery.

Prophylaxis for post-perfusion CABG bleeding.

Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials

Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban

Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass

The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients.

Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.

Similar Documents

Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia

Thrombosis due to Heparin-induced Thrombocytopenia in Cardiac Surgery : is Fondaparinux an Effective Treatment ?

Heparin-induced thrombocytopenia occurring after discontinuation of heparin.

Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery.

Prophylaxis for post-perfusion CABG bleeding.

Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials

Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban

Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass

The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients.

Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation.